Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …

Lymphomas are solid tumours of the immune system. Hodgkin's lymphoma accounts for
about 10% of all lymphomas, and the remaining 90% are referred to as non-Hodgkin …

The purpose of this work was to modernize recommendations for evaluation, staging, and
response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma …

The purpose of this article is to review the status and limitations of anatomic tumor response
metrics including the World Health Organization (WHO) criteria, the Response Evaluation …

Purpose Standardized response criteria are needed to interpret and compare clinical trials
and for approval of new therapeutic agents by regulatory agencies. Methods The …

Abstract PET using 18 F-FDG for treatment monitoring in patients with lymphoma is one of
the most well-developed clinical applications. PET/CT is nowadays used during treatment to …

Multiple biomedical imaging techniques are used in all phases of cancer management.
Imaging forms an essential part of cancer clinical protocols and is able to furnish …

Purpose To develop guidelines for performing and interpreting positron emission
tomography (PET) imaging for treatment assessment in patients with lymphoma both in …

PURPOSE Burkitt lymphoma is an aggressive B-cell lymphoma curable with dose-intensive
chemotherapy derived from pediatric leukemia regimens. Treatment is acutely toxic with late …

Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and
clinical behavior. Patients typically present with persistent painless lymphadenopathy, but …